Immatics
| Immatics
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
17 of 75
Related slides by other companies
Kiromic BioPharma
Investor Presentation
May 2023
upcoming milestones authorization to evaluate in non small cell lung cancer may beginning of first in human trial activation for data results from first patient in clinical trial by end of initiation of clinical trials expansion cohort submission of new for and | Kiromic BioPharma
Erasca
Investor Presentation
January 2024
clinical development plan generates multiple ways to win for patients | Erasca
Babylon
Investor Conference
January 2023
our led platform has been purpose built to maximize functionality utilize data intelligently drive patient engagement and enhance operational efficiency led | Babylon
BenevolentAI
Investor Presentation
October 2022
ben phase progressing phase double blind placebo controlled in patient two part clinical study day day day day active recruiting sites in the in a further sites under approval recruitment completion anticipated our intention is to to partner this asset with a pharmaceutical company that has a focus in dermatology for continued clinical development and if approved our intention is to out development and of ben following completion of this trial with key big and dermatology specialists as potential part | BenevolentAI
Other recent decks by Immatics
See all presentations (2 decks)
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights